Human BRCA1 associated RING domain protein 1 (BARD1) ELISA Kit | BARD1 elisa kit

Human BRCA1 associated RING domain protein 1 (BARD1) ELISA Kit

Cat. Num. AAA7236583

• Reactivity: Human
• Synonyms: BRCA1 associated RING domain protein 1 (BARD1); Human BRCA1 associated RING domain protein 1 (BARD1) ELISA Kit; BARD1 elisa kit

• Reactivity: Human
• Specificity: This assay has high sensitivity and excellent specificity for detection of BARD1. No significant cross-reactivity or interference between BARD1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between BARD1 and all the analogues, therefore, cross reaction may still exist in some cases.

• Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate
• Assay Type: Quantitative Competitive
• Sensitivity: 0.1 ng/mL
• Preparation and Storage: Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Related Product Information for BARD1 elisa kit

Intended Uses: This BARD1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of HumanBARD1. This ELISA kit for research use only, not for therapeutic or test applications!

Principle of the Assay: BARD1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-BARD1 antibody and an BARD1-HRP conjugate. The assay sample and buffer are incubated together with BARD1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the BARD1 concentration since BARD1 from samples and BARD1-HRP conjugate compete for the anti-BARD1 antibody binding site. Since the number of sites is limited, as more sites are occupied by BARD1 from the sample, fewer sites are left to bind BARD1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The BARD1 concentration in each sample is interpolated from this standard curve.

Product Categories/Family for BARD1 elisa kit

Epigenetics and Nuclear Signaling

NCBI and Uniprot Product Information

• NCBI GI #: 157266328
• NCBI GeneID: 580
• NCBI Accession #: NP_000456.2
• NCBI GenBank Nucleotide #: NM_000465.3
• Molecular Weight: 14,362 Da
• NCBI Official Full Name: BRCA1-associated RING domain protein 1 isoform 1
• NCBI Official Synonym Full Names: BRCA1 associated RING domain 1
• NCBI Official Symbol: BARD1
• NCBI Protein Information: BRCA1-associated RING domain protein 1; BRCA1-associated RING domain gene 1
• UniProt Protein Name: BRCA1-associated RING domain protein 1
• Protein Family: BRCA1-associated RING domain protein
• UniProt Gene Name: BARD1
• UniProt Synonym Gene Names: BARD-1
• UniProt Entry Name: BARD1_HUMAN

NCBI Description

This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]

Uniprot Description

BARD1: the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage. Colocalizes with BRCA1 into discrete subnuclear foci during S phase. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex. Defects in BARD1 gene are found in primary breast, ovarian and uterine cancers.

Protein type: EC 6.3.2.19; Ubiquitin ligase; EC 6.3.2.-; Ligase; Ubiquitin conjugating system

Chromosomal Location of Human Ortholog: 2q35

Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; BRCA1-BARD1 complex; nucleolus; nucleus; ubiquitin ligase complex

Molecular Function: protein binding; protein homodimerization activity; zinc ion binding; RNA binding; protein heterodimerization activity; ubiquitin-protein ligase activity; kinase binding; ligase activity

Biological Process: negative regulation of mRNA 3'-end processing; negative regulation of protein export from nucleus; regulation of phosphorylation; positive regulation of apoptosis; tissue homeostasis; positive regulation of protein catabolic process; protein ubiquitination; DNA repair; cell cycle arrest; response to DNA damage stimulus; negative regulation of apoptosis

Disease: Breast Cancer